Summary
Torasemide 40 mg/day p.o. was administered for 21 days to 8 healthy volunteers to investigate its pharmacodynamics, pharmacokinetics and safety on chronic administration. It induced a highly significant initial increase in 24-h urinary volume and 24-h excretion of sodium and chloride, but its affect diminished after the first days. On Days 0, 1, 10 and 21 the experiement was divided in 3 clearance phases, extending from 0 to 2 h, 2 to 6 h and 6 to 24 h after dosing. The fractional excretion of sodium, chloride, potassium, calcium, magnesium and inorganic phosphates peaked during the first 2 h and returned almost to the control value during the following two clearance phases. The phase-dependent changes were significant for all electrolytes, except for potassium and inorganic phosphate. Plasma electrolyte levels remained constant throughout the study, except for a small decrease in chloride and potassium and for an increase in calcium and magnesium. Fasting blood glucose and glucose tolerance test were unaffected. A small but significant decrease in LDL-cholesterol was observed on Day 10. Other plasma lipid components showed minor changes. Plasma uric acid levels were moderately increased. There was no significant change of the creatinine clearance. Body weight fell significantly (by about 2 kg) during the study. Tonal audiometry was normal before and after the study. There was no significant difference between the plasma levels of torasemide on Days 1, 10 and 21, nor between its elimination half-life on Days 1 and 21. Side-effects consisted mainly of fatigue and low-back pain on days of intense diuresis. There were no toxic symptoms. ECG recordings and blood pressure remained within normal limits.
Similar content being viewed by others
References
Lesne M, Clerckx-Braun F, Duhoux P, van Ypersele de Strihoux Ch (1982) Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol 20 [8]: 382–397
Scheen AJ, Delarge J, Luyckx AS (1986) Dose-response curve for the new diuretic torasemide in healthy volunteers. Eur J Clin Pharmacol 31 [Suppl]: 35–42
Morgan DB, Davidson C (1980) Hypokalaemia and diuretics: An analysis of publications. Br Med J 62 [8]: 905–908
Roberts CJC, Homeida M, Roberts F (1978) Effect of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects. Br J Clin Pharmacol 6: 129–133
Steele H, Oppenheimer S (1969) Factors affecting urate excretion following diuretic administration in man. Am J Med 47: 564–574
Reutter F, Schaub F (1964) Harnsäurestoffwechsel und Salidiuretika. Dtsch Med Wochenschr 89: 1101–1104
Heimsoth V, Hartmann F (1965) Untersuchungen zur Störung des Harnsäurestoffwechsels nach Saliuretika-Verabreichung. Dtsch Med Wochenschr 90: 1905–1908
Amery A, de Schaepdryver A (1981) for the European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in patients above age sixty. In: Onesti G, Eun Kim K (eds) Hypertension in the young and old. Grune and Stratton, New York, pp 315–326
Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT (1982) Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 2: 1293–1295
Joos C, Kewitz H, Reinhold-Kourniati D (1980) Effects of diuretics on plasma lipoproteins in healthy men. Eur J Clin Pharmacol 17: 251–257
Gluck Z, Weidman P, Mordasani R, Peheim E, Backmann G, Keusch G, Riesen W (1979) Einfluß einer Diureticatherapie auf die Serumlipoproteins: ein unerwünschter Effekt? Schweiz Med Wochenschr 109: 104–108
Grimm RH Jr, Leon A, Hunninghake D, Hannon P, Blackburn H (1979) Increased lipids and lipoproteins in diuretictreated mild hypertension. Am J Cardiol 43 [2]: 419
Rosenthal T, Holtzman E, Segal P (1980) The effect of chlortalidone on serum lipids and lipoproteins. Atherosclerosis 36 [1]: 111–115
Goldman AI, Steele BW, Schnaper HW, Fitz AE, Frohlich ED, Perry HM (1980) Serum lipoprotein levels during chlortalidone therapy. J Am Med Assoc 244 [15]: 1691–1695
Hanze S, Seyberth H (1967) Untersuchungen zur Wirkung der Diuretica Furosemid, Ethacrynsäure und Triamterene auf die renale Magnesium und Calciumausscheidung. Klin Wochenschr 45: 313
Reyes AJ, Learly W (1982) Magnesiuric effect of a single dose of furosemide in healthy adults. Curr Ther Res Clin Exp 32: 406–416
Duarte CG, Winnacker J, Becker K, Pace A (1971) Thiazideinduced hypercalcemia. N Engl J Med 284: 828–830
Middler S, Pak CYC, Murad F, Bartier FC (1979) Thiazide diuretics and calcium metabolism. Metabolism 22: 139–146
Lim P, Jacob E (1972) Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J 3: 620–622
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ambroes, Y., Ronflette, I. & Dodion, L. Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects. Eur J Clin Pharmacol 31 (Suppl 1), 1–7 (1986). https://doi.org/10.1007/BF00541460
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541460